帕博利珠单抗联合新辅助化疗可提高雄激素受体阳性且肿瘤浸润淋巴细胞低的三阴性乳腺癌患者的病理完全缓解率。 - Suppr | 超能文献

Pembrolizumab added to neoadjuvant chemotherapy may improve pathological complete response in androgen-receptor positive and low tumor-infiltrating lymphocytes triple-negative breast cancer patients.

作者信息

Altundag Kadri

机构信息

Tepe Prime, MKA Breast Cancer Clinic, 06800, Ankara, Turkey.

出版信息

Breast Cancer. 2025 Mar;32(2):456. doi: 10.1007/s12282-025-01672-z. Epub 2025 Jan 29.

DOI:10.1007/s12282-025-01672-z

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Pembrolizumab added to neoadjuvant chemotherapy may improve pathological complete response in androgen-receptor positive and low tumor-infiltrating lymphocytes triple-negative breast cancer patients.帕博利珠单抗联合新辅助化疗可提高雄激素受体阳性且肿瘤浸润淋巴细胞低的三阴性乳腺癌患者的病理完全缓解率。

Breast Cancer. 2025 Mar;32(2):456. doi: 10.1007/s12282-025-01672-z. Epub 2025 Jan 29.

2

Reply to the letter to the editor "Pembrolizumab added to neoadjuvant chemotherapy may improve pathological complete response in androgen-receptor positive and low tumor-infiltrating lymphocytes triple-negative breast cancer patients".致编辑的信的回复：“帕博利珠单抗联合新辅助化疗可能改善雄激素受体阳性且肿瘤浸润淋巴细胞低的三阴性乳腺癌患者的病理完全缓解”

Breast Cancer. 2025 Jul;32(4):881. doi: 10.1007/s12282-025-01703-9. Epub 2025 Apr 13.

3

Programmed cell death protein 1 is a marker for neoadjuvant chemotherapy response in triple-negative breast cancer.程序性细胞死亡蛋白 1 是三阴性乳腺癌新辅助化疗反应的标志物。

Rev Assoc Med Bras (1992). 2023 Sep 18;69(9):e20230276. doi: 10.1590/1806-9282.20230276. eCollection 2023.

4

T-cell immune checkpoint inhibition plus hypomethylation for locally advanced HER2-negative breast cancer: a phase 2 neoadjuvant window trial of decitabine and pembrolizumab followed by standard neoadjuvant chemotherapy.T细胞免疫检查点抑制联合低甲基化治疗局部晚期HER2阴性乳腺癌：地西他滨和帕博利珠单抗序贯标准新辅助化疗的2期新辅助窗口期试验

J Immunother Cancer. 2025 Feb 27;13(2):e010294. doi: 10.1136/jitc-2024-010294.

5

Efficacy and feasibility of neoadjuvant pembrolizumab plus chemotherapy for early-stage triple-negative and estrogen receptor low, HER2-negative breast cancer: a Japanese single-institution real-world study.新辅助派姆单抗联合化疗治疗早期三阴性及雌激素受体低、人表皮生长因子受体2阴性乳腺癌的疗效与可行性：一项日本单机构真实世界研究

Breast Cancer. 2025 Mar;32(2):329-336. doi: 10.1007/s12282-024-01657-4. Epub 2024 Dec 7.

6

Pembrolizumab for Early Triple-Negative Breast Cancer.帕博利珠单抗治疗早期三阴性乳腺癌。

N Engl J Med. 2020 Feb 27;382(9):810-821. doi: 10.1056/NEJMoa1910549.

7

TROPION-Breast04: a randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-naïve early-stage triple negative or HR-low/HER2- breast cancer.TROPION-Breast04：一项关于新辅助达妥昔单抗（Dato-DXd）联合度伐利尤单抗治疗，随后辅助使用度伐利尤单抗与初治早期三阴性或激素受体低表达/人表皮生长因子受体2阴性乳腺癌患者的标准治疗方案对比的随机III期研究。

Ther Adv Med Oncol. 2025 Feb 5;17:17588359251316176. doi: 10.1177/17588359251316176. eCollection 2025.

8

A phase II, randomized, open-labeled study to evaluate low-dose pembrolizumab in addition to neoadjuvant chemotherapy for triple-negative breast cancer (TNBC).一项II期随机开放标签研究，旨在评估低剂量帕博利珠单抗联合新辅助化疗用于三阴性乳腺癌（TNBC）的疗效。

Trials. 2025 Feb 27;26(1):73. doi: 10.1186/s13063-025-08726-9.

9

Clinicopathological significance of androgen receptor expression and tumor infiltrating lymphocytes in triple-negative breast cancer: a retrospective cohort study.雄激素受体表达及肿瘤浸润淋巴细胞在三阴性乳腺癌中的临床病理意义：一项回顾性队列研究

Breast Cancer. 2025 Mar;32(2):357-368. doi: 10.1007/s12282-024-01662-7. Epub 2024 Dec 27.

10

Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study.帕博利珠单抗联合化疗作为高危早期三阴性乳腺癌的新辅助治疗：来自 1b 期开放标签、多队列 KEYNOTE-173 研究的结果。

Ann Oncol. 2020 May;31(5):569-581. doi: 10.1016/j.annonc.2020.01.072. Epub 2020 Feb 14.

本文引用的文献

1

Clinicopathological significance of androgen receptor expression and tumor infiltrating lymphocytes in triple-negative breast cancer: a retrospective cohort study.雄激素受体表达及肿瘤浸润淋巴细胞在三阴性乳腺癌中的临床病理意义：一项回顾性队列研究

Breast Cancer. 2025 Mar;32(2):357-368. doi: 10.1007/s12282-024-01662-7. Epub 2024 Dec 27.

2

Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer.帕博利珠单抗治疗早期三阴性乳腺癌的总生存期。

N Engl J Med. 2024 Nov 28;391(21):1981-1991. doi: 10.1056/NEJMoa2409932. Epub 2024 Sep 15.